TNF Pharmaceuticals Inc. (TNFA)
0.37
-0.03 (-8.44%)
At close: Apr 04, 2025, 3:42 PM
-8.44% (1D)
| Bid | 0.36 |
| Market Cap | 1.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -13.54 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.39 |
| Volume | 2,568,161 |
| Avg. Volume (20D) | 806,244 |
| Open | 0.40 |
| Previous Close | 0.40 |
| Day's Range | 0.36 - 0.42 |
| 52-Week Range | 0.33 - 3.50 |
| Beta | 2.48 |
About TNFA
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to d...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 6
Stock Exchange NASDAQ
Ticker Symbol TNFA
Website https://tnfpharma.com
2 months ago
-9.4%
TNF Pharmaceuticals shares are trading higher afte...
Unlock content with
Pro Subscription
3 months ago
+13.71%
TNF Pharmaceuticals shares are trading higher after the company reported statistically significant results for its Phase 2a trial of Sarcopenia treatment at an international conference. The Phase 2B study is expected to take place in early 2025.
